14.10.2013 23:27:07
|
Portola Pharma Announces First Phase 2 Results Of Andexanet Alfa
(RTTNews) - Portola Pharmaceuticals, Inc. (PTLA) announced new interim findings from a Phase 2 proof-of-concept study of its investigational Factor Xa inhibitor antidote, Andexanet alfa, in healthy volunteers who received the Factor Xa inhibitor Eliquis.
Thye company said thye Andexanet alfa was administered intravenously as a bolus followed by a continuous infusion for up to two hours. Data from this study showed a rapid and nearly complete reversal of the anticoagulation effect of Eliquis measured at two minutes following completion of the bolus, which was sustained during infusion for up to two hours.
Portola stated that the new interim findings demonstrated that two minutes after completion of a 420 mg bolus dose of Andexanet alfa, the anticoagulant activity of Eliquis was reversed by about 92% as measured by anti-Factor Xa activity compared with placebo. At the end of the two-hour infusion, the anticoagulation activity of Eliquis remained reversed by approximately 91%.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Portola Pharmaceuticals Incmehr Nachrichten
Keine Nachrichten verfügbar. |